Compounds > raloxifene hydrochloride
Page last updated: 2024-08-23

raloxifene hydrochloride and mocetinostat

raloxifene hydrochloride has been researched along with mocetinostat in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bryan, N; Zuckerman, SH1
Asakura, M; Asanuma, H; Hori, M; Kitakaze, M; Liao, Y; Mori, H; Node, K; Ogita, H; Sanada, S; Shinozaki, Y; Takashima, S1
Cano, A; Hermenegildo, C; Oviedo, PJ; Tarín, JJ1
Aurrekoetxea, I; del Agua, AR; Elorriaga, MA; Guéraud, F; Rodriguez, F; Ruiz-Larrea, MB; Ruiz-Sanz, JI1
Bracht, A; Campos, LB; Ishii-Iwamoto, EL; Martins-Maciel, ER; Salgueiro-Pagadigorria, CL1

Other Studies

5 other study(ies) available for raloxifene hydrochloride and mocetinostat

ArticleYear
Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL).
    Atherosclerosis, 1996, Sep-27, Volume: 126, Issue:1

    Topics: Animals; Antioxidants; Copper; Dexamethasone; Estradiol; Estrogen Antagonists; Free Radicals; Horseradish Peroxidase; Humans; Lipoproteins, LDL; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Oxidation-Reduction; Peroxidase; Phagocytosis; Piperidines; Probucol; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Thiobarbituric Acid Reactive Substances; Thiophenes; Tyrosine

1996
Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart.
    Journal of the American College of Cardiology, 2002, Sep-04, Volume: 40, Issue:5

    Topics: Animals; Charybdotoxin; Dogs; Enzyme Inhibitors; Mitogen-Activated Protein Kinase Kinases; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Peroxidase; Potassium Channels, Calcium-Activated; Raloxifene Hydrochloride; Reperfusion Injury; Selective Estrogen Receptor Modulators

2002
Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2alpha-isoprostane levels in postmenopausal women.
    Fertility and sterility, 2005, Volume: 84, Issue:6

    Topics: Antioxidants; Biomarkers; Cardiovascular Diseases; F2-Isoprostanes; Female; Humans; Middle Aged; Neutrophils; Oxidative Stress; Peroxidase; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators

2005
Involvement of G-463A MPO gene polymorphism in the response of postmenopausal women to hormone therapy.
    Menopause (New York, N.Y.), 2011, Volume: 18, Issue:5

    Topics: Acetylcysteine; alpha-Tocopherol; Antioxidants; Estradiol; Female; Hormone Replacement Therapy; Humans; Intercellular Adhesion Molecule-1; Lipids; Malondialdehyde; Middle Aged; Peroxidase; Polymorphism, Genetic; Postmenopause; Progesterone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uric Acid

2011
Raloxifene affects fatty acid oxidation in livers from ovariectomized rats by acting as a pro-oxidant agent.
    Toxicology letters, 2013, Feb-13, Volume: 217, Issue:1

    Topics: Acyl Coenzyme A; Acyl-CoA Oxidase; Animals; Chemical and Drug Induced Liver Injury; Disease Progression; Estrogen Replacement Therapy; Fatty Acids; Fatty Liver; Female; Hydrogen Peroxide; Liver; Mitochondria, Liver; Ovariectomy; Oxidants; Oxidation-Reduction; Peroxidase; Peroxisomes; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators

2013